1. Signaling Pathways
  2. GPCR/G Protein
  3. GCGR

GCGR

Glucagon Receptor

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity
  • HY-13443
    Exendin-4
    Agonist 99.98%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P0014
    Liraglutide
    Agonist 99.68%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
  • HY-P0082
    Glucagon (1-29), bovine, human, porcine
    99.81%
    Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation.
  • HY-114118
    Semaglutide
    Agonist 99.84%
    Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
  • HY-P1731B
    Tirzepatide hydrochloride
    Agonist 99.82%
    Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
  • HY-P3463
    Beinaglutide
    99.47%
    Beinaglutide is a recombinant human GLP-1 (rhGLP-1) polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH).
  • HY-P2221B
    Glepaglutide acetate
    Agonist 98.06%
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
  • HY-P3506
    LY3437943
    Antagonist
    LY3437943 is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). LY3437943 inhibits for human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. LY3437943 can be used for the research of obesity.
  • HY-P0264
    Avexitide
    Antagonist 99.81%
    Avexitide (Exendin (9-39)) is a specific and competitive GLP-1 receptor antagonist.
  • HY-P0055
    GLP-1(7-37)
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
  • HY-19904
    Adomeglivant
    Antagonist 98.18%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
  • HY-50663
    MK 0893
    Antagonist 99.85%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
  • HY-P0054
    GLP-1(7-36), amide acetate
    98.62%
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
  • HY-P0055A
    GLP-1(7-37) acetate
    99.33%
    GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
  • HY-P1141
    GLP-1(9-36)amide
    Antagonist 99.78%
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor.
  • HY-114118A
    Semaglutide TFA
    Agonist 99.90%
    Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
  • HY-112185
    LY3502970
    Agonist 98.31%
    LY3502970 (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
  • HY-13443A
    Exendin-4 acetate
    Agonist 99.44%
    Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P2625
    GLP-2(3-33)
    Agonist 99.32%
    GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM).
  • HY-103546
    BETP
    Agonist 99.28%
    BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
Cat. No. Product Name / Synonyms Species Source